Saponin Adjuvant Enhances Vaccine Response in Nonhuman Primates
Author Information
Author(s): Yousefpour Parisa, Zhang Yiming J, Maiorino Laura, Melo Mariane B, Arainga Ramirez Mariluz A, Kumarapperuma Sidath C, Xiao Peng, Silva Murillo, Li Na, Michaels Katarzyna K, Georgeson Erik, Eskandarzadeh Saman, Kubitz Michael R, Groschel Bettina, Qureshi Kashif, Fontenot Jane, Hangartner Lars, Nedellec Rebecca, Love J Christopher, Burton Dennis R, Schief William R, Villinger Francois J, Irvine Darrell J
Primary Institution: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Hypothesis
Does the saponin/monophosphoryl lipid A nanoparticle (SMNP) adjuvant elicit stronger immune responses compared to aluminum hydroxide in nonhuman primates?
Conclusion
The study found that SMNP significantly enhances immune responses compared to alum, promoting stronger antibody production and immune cell activation.
Supporting Evidence
- SMNP elicited 7-fold higher peak antigen-specific germinal center B-cell responses than alum.
- SMNP induced 18-fold higher autologous neutralizing antibody titers compared to alum.
- SMNP promoted rapid antigen accumulation in both proximal and distal lymph nodes.
- SMNP triggered strong type I interferon transcriptional signatures in lymph nodes.
- SMNP increased levels of antigen-specific plasma and memory B cells.
Takeaway
A new vaccine helper called SMNP works better than an old one called alum, helping the body make more antibodies to fight germs.
Methodology
Nonhuman primates were immunized with a stabilized HIV envelope trimer immunogen and compared immune responses elicited by SMNP and alum.
Limitations
The study was limited to nonhuman primates and may not fully translate to human responses.
Participant Demographics
Female Indian Rhesus macaques aged 3-4 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website